Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

David V. Gold

Center for Molecular Medicine and Immunology

Garden State Cancer Center

Morris Plains

NJ 07950

USA

[email]@gscancer.org

Name/email consistency: high

[Claim this account]

Affiliations

Center for Molecular Medicine and Immunology, Garden State Cancer Center, Morris Plains, NJ 07950, USA. 2004 - 2013
Garden State Cancer Center, Belleville, New Jersey 07109, USA. 2003

References

PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma. Gold, D.V., Gaedcke, J., Ghadimi, B.M., Goggins, M., Hruban, R.H., Liu, M., Newsome, G., Goldenberg, D.M. Cancer (2013) [Pubmed]
Detection of early-stage pancreatic adenocarcinoma. Gold, D.V., Goggins, M., Modrak, D.E., Newsome, G., Liu, M., Shi, C., Hruban, R.H., Goldenberg, D.M. Cancer Epidemiol. Biomarkers Prev. (2010) [Pubmed]
Enhanced expression of CD74 in gastrointestinal cancers and benign tissues. Gold, D.V., Stein, R., Burton, J., Goldenberg, D.M. Int. J. Clin. Exp. Pathol (2010) [Pubmed]
A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma. Gold, D.V., Goldenberg, D.M., Karacay, H., Rossi, E.A., Chang, C.H., Cardillo, T.M., McBride, W.J., Sharkey, R.M. Cancer Res. (2008) [Pubmed]
PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Gold, D.V., Karanjawala, Z., Modrak, D.E., Goldenberg, D.M., Hruban, R.H. Clin. Cancer Res. (2007) [Pubmed]
New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. Gold, D.V., Modrak, D.E., Ying, Z., Cardillo, T.M., Sharkey, R.M., Goldenberg, D.M. J. Clin. Oncol. (2006) [Pubmed]
Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft. Gold, D.V., Modrak, D.E., Schutsky, K., Cardillo, T.M. Int. J. Cancer (2004) [Pubmed]
Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer. Gold, D.V., Schutsky, K., Modrak, D., Cardillo, T.M. Clin. Cancer Res. (2003) [Pubmed]

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.